At the Asembia 2026 Summit, Syneos Health host Chris Van Denburg sits down with Dale Lippert, Executive Director, CAR T Patient Support and Services at Autolus Therapeutics, to explore the operational realities behind CAR T patient support programs for relapsed/refractory acute lymphoblastic leukemia (ALL). Drawing on decades of experience launching CAR T therapies, Dale shares practical insights into how organizations can design patient support models that reduce delays, improve coordination and strengthen the patient and caregiver experience.

The conversation examines the trade-offs between outside hub models and internal hub-and-spoke approaches, including considerations around scalability, governance, flexibility, data visibility and operational readiness. Dale also outlines why many organizations are moving toward hybrid models that balance outsourced administrative support with in-house management of high-risk escalations, site relationships and cross-functional coordination.

Also hear how effective CAR T patient support programs are built around urgency, transparency and continuous communication. From benefits verification and scheduling coordination to manufacturing logistics and caregiver readiness, Dale explains why reducing friction across every step of the patient journey can have a meaningful impact on treatment timelines and patient outcomes.

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Recorded from the floor of Asembia 2026, this episode explores how biopharma leaders are rethinking reimbursement, patient access and commercial strategy in an increasingly complex market. Host Kim Plesnarski is joined by Brian Siemak, VP of Portfolio Strategy at MannKind, and Terry Milton, AVP Field Reimbursement at Eli Lilly, to continue their on-stage panel discussion on the mounting pressure across gross-to-net, patient support and market access models.

The conversation examines how evolving payer structures, consumer-driven healthcare decisions and new distribution models are reshaping the patient journey. The group also discusses the growing role of AI and emerging technologies, emphasizing the need to use innovation as an efficiency driver rather than a replacement for human expertise.

Throughout the episode, the panel challenges traditional partnership and launch models, advocating for more collaborative, outcomes-focused approaches built around speed, flexibility and shared accountability. From designing for real-world market conditions to preparing teams to pivot quickly, the discussion offers practical insights for organizations looking to modernize commercialization strategies and improve patient access in a rapidly changing healthcare landscape.

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Recorded on the ground at the Asembia Summit 2026, this episode explores how stronger collaboration, connected care models and patient-centered listening can improve access, affordability and outcomes in oncology care. Host Chris Van Denburg sits down with Micaila Ruiz, PharmD, MPH, Vice President, Clinical Operations, Pharmacy Care Services at Optum, to discuss the evolving role of specialty pharmacy and the growing need for more coordinated, holistic support for patients navigating increasingly complex treatment journeys.

From integrating pharmacy services to improving communication across providers, manufacturers and specialty pharmacy partners, the conversation highlights the opportunities to reduce friction and create a more seamless patient experience. Together, Chris and Micaila discuss what it will take to strengthen the foundation of the healthcare ecosystem as new therapies, biomarker-driven treatments and chronic cancer management continue to reshape patient expectations and outcomes.

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode of Conversations on Commercialization, host Michael Sarshad, Managing Director, Consulting at Syneos Health, talks with KAI CEO David Williams and Deanne Melloy, CCO Deployment Solutions at Syneos Health, about how AI can help commercial teams improve call quality, coaching, field visibility and sales rep performance. They discuss why activity metrics fall short, how AI-enabled listening creates faster feedback loops and what leaders can do to drive better HCP engagement and commercial impact.

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode, Tyler Cowan, VP, Commercial speaks with Paul Rittman, President and General Manager of Almirall US, about how payer consolidation and PBM influence are reshaping dermatology commercialization.

They discuss how pharmaceutical companies must adapt launch strategy, market access planning and clinical differentiation to succeed in today’s competitive specialty landscape. The conversation explores the growing role of digital engagement, direct-to-consumer (DTC) strategy, telehealth and cash-pay models in improving patient access.

Listeners will gain practical insights into how innovation, payer strategy and patient-centric commercialization drive success in dermatology and specialty pharma.

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

What if drug naming could be faster, smarter and more aligned to brand strategy?

In this episode, Addison Whitney’s Joe Daley, President, and Bill Purdy, SVP and Managing Director of Global Brand Development & Strategy, break down how Ari™, a purpose-built AI platform, is solving long-standing naming and branding challenges in biopharma.

Listen and you’ll learn:

• How Ari™ integrates strategic input, trademark search and POCA screening
• Ways AI reduces attrition and regulatory risk in naming
• Why naming is now a strategic process and not just a creative one

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Recorded at Fierce Pharma Week 2025, the conversation continues with part two of our conversation with Mark Bard, co-founder of the Digital Health Coalition.

In this episode, Bard and host Tyler Cowan turn the lens to patients, exploring how direct-to-patient models are disrupting traditional care and the implications of reduced physician involvement. They also tackle the rise of agentic AI, what it could enable and what commercial teams should be thinking about now.

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Recorded at Fierce Pharma Week 2025, here is the first episode in a two-part series with Mark Bard, co-founder of the Digital Health Coalition.

In this episode, Bard joins host Tyler Cowan, VP, Commercial at Syneos Health to unpack how the pandemic reshaped provider expectations and the continued impact on commercial teams. From feedback loops to content fatigue, to the myth of multichannel mastery, they break down what it takes to engage HCPs on their terms.

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.